Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1957 1
1958 3
1959 1
1964 1
1965 2
1966 10
1967 19
1968 18
1969 31
1970 13
1971 13
1972 23
1973 20
1974 38
1975 12
1976 23
1977 22
1978 21
1979 20
1980 20
1981 19
1982 22
1983 33
1984 31
1985 37
1986 21
1987 25
1988 29
1989 24
1990 30
1991 42
1992 13
1993 14
1994 18
1995 32
1996 29
1997 27
1998 23
1999 33
2000 42
2001 29
2002 37
2003 38
2004 38
2005 32
2006 39
2007 46
2008 50
2009 64
2010 55
2011 55
2012 60
2013 59
2014 54
2015 50
2016 45
2017 64
2018 62
2019 66
2020 69
2021 63
2022 58
2023 57
2024 23

Text availability

Article attribute

Article type

Publication date

Search Results

1,931 results

Results by year

Filters applied: . Clear all
Page 1
Targeted Therapies in Pheochromocytoma and Paraganglioma.
Wang K, Crona J, Beuschlein F, Grossman AB, Pacak K, Nölting S. Wang K, et al. J Clin Endocrinol Metab. 2022 Nov 23;107(11):2963-2972. doi: 10.1210/clinem/dgac471. J Clin Endocrinol Metab. 2022. PMID: 35973976 Free PMC article. Review.
Some tyrosine kinase inhibitors (sunitinib, cabozantinib) are already in clinical use with some promising results, but without formal approval for the treatment of PPGLs. Sunitinib is the only therapeutic option which has been investigated in a randomized placebo-co …
Some tyrosine kinase inhibitors (sunitinib, cabozantinib) are already in clinical use with some promising results, but without formal …
Pheochromocytoma, diagnosis and treatment: Review of the literature.
Farrugia FA, Martikos G, Tzanetis P, Charalampopoulos A, Misiakos E, Zavras N, Sotiropoulos D. Farrugia FA, et al. Endocr Regul. 2017 Jul 1;51(3):168-181. doi: 10.1515/enr-2017-0018. Endocr Regul. 2017. PMID: 28858847 Free article. Review.
RESULTS: More than four times elevation of plasma fractionated metanephrines or elevated 24-h urinary fractionated metanephrines are keys to diagnosing pheochromocytoma. If the results are equivocal then we perform the clonidine test. ...If there is a risk of the hereditab …
RESULTS: More than four times elevation of plasma fractionated metanephrines or elevated 24-h urinary fractionated metanephrines are keys to …
Endocrine Fever.
Kalra S, Bhattacharya S, Dhingra A, Khare J, Jindal S. Kalra S, et al. J Pak Med Assoc. 2024 May;74(5):998-999. doi: 10.47391/JPMA.24-36. J Pak Med Assoc. 2024. PMID: 38783456 Free article. Review.
Additionally, several endocrine disorders, including hyperthyroidism, subacute thyroiditis, carcinoid syndrome, and pheochromocytoma, can manifest as fever. Furthermore, fever can be an adverse effect of various endocrine treatments, such as bisphosphonates and antithyroid …
Additionally, several endocrine disorders, including hyperthyroidism, subacute thyroiditis, carcinoid syndrome, and pheochromocytoma, …
Radiopharmaceuticals for Neuroendocrine Tumors.
Chin RI, Wu FS, Menda Y, Kim H. Chin RI, et al. Semin Radiat Oncol. 2021 Jan;31(1):60-70. doi: 10.1016/j.semradonc.2020.07.007. Semin Radiat Oncol. 2021. PMID: 33246637 Review.
Peptide receptor radionuclide therapy (PRRT) has emerged as a promising therapeutic option for patients with locally advanced and/or metastatic disease refractory to standard of care treatment. The landmark international phase III NETTER-1 trial led to the approval of (177 …
Peptide receptor radionuclide therapy (PRRT) has emerged as a promising therapeutic option for patients with locally advanced and/or metasta …
I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma.
Carrasquillo JA, Pandit-Taskar N, Chen CC. Carrasquillo JA, et al. Semin Nucl Med. 2016 May;46(3):203-14. doi: 10.1053/j.semnuclmed.2016.01.011. Semin Nucl Med. 2016. PMID: 27067501 Review.
Because these tumors are rare, most therapy studies are retrospective presentations of clinical experience. Numerous retrospective studies and a few prospective studies have shown favorable responses in this disease, including symptomatic, biochemical, and objective respon …
Because these tumors are rare, most therapy studies are retrospective presentations of clinical experience. Numerous retrospective st …
Malignant pheochromocytoma and paraganglioma: management options.
Corssmit EPM, Snel M, Kapiteijn E. Corssmit EPM, et al. Curr Opin Oncol. 2020 Jan;32(1):20-26. doi: 10.1097/CCO.0000000000000589. Curr Opin Oncol. 2020. PMID: 31599769 Review.
PURPOSE OF REVIEW: Although the majority of pheochromocytoma and paraganglioma are benign, 15-17% develop metastatic disease, being present at the initial diagnosis in about 11-31% of cases. ...For individual patients, overall survival, progression-free survival, and cl …
PURPOSE OF REVIEW: Although the majority of pheochromocytoma and paraganglioma are benign, 15-17% develop metastatic disease, being p …
Efficacy of alpha-Blockers on Hemodynamic Control during Pheochromocytoma Resection: A Randomized Controlled Trial.
Buitenwerf E, Osinga TE, Timmers HJLM, Lenders JWM, Feelders RA, Eekhoff EMW, Haak HR, Corssmit EPM, Bisschop PHLT, Valk GD, Veldman RG, Dullaart RPF, Links TP, Voogd MF, Wietasch GJKG, Kerstens MN. Buitenwerf E, et al. J Clin Endocrinol Metab. 2020 Jul 1;105(7):2381-91. doi: 10.1210/clinem/dgz188. J Clin Endocrinol Metab. 2020. PMID: 31714582 Free PMC article. Clinical Trial.
DESIGN: Randomized controlled open-label trial (PRESCRIPT; ClinicalTrials.gov NCT01379898). ...Phenoxybenzamine was more effective in preventing intraoperative hemodynamic instability, but it could not be established whether this was associated with a better clin …
DESIGN: Randomized controlled open-label trial (PRESCRIPT; ClinicalTrials.gov NCT01379898). ...Phenoxybenzamine was more effec …
Management of adrenal tumors in pregnancy.
Eschler DC, Kogekar N, Pessah-Pollack R. Eschler DC, et al. Endocrinol Metab Clin North Am. 2015 Jun;44(2):381-97. doi: 10.1016/j.ecl.2015.02.006. Endocrinol Metab Clin North Am. 2015. PMID: 26038207 Review.
Adrenal diseases, including Cushing syndrome (CS), primary aldosteronism (PA), pheochromocytoma, and adrenocortical carcinoma, are uncommon in pregnancy; a high degree of clinical suspicion must exist. ...However, catecholamines are not altered in pregnancy and allo …
Adrenal diseases, including Cushing syndrome (CS), primary aldosteronism (PA), pheochromocytoma, and adrenocortical carcinoma, are un …
I-131-MIBG therapies.
Vöö S, Bucerius J, Mottaghy FM. Vöö S, et al. Methods. 2011 Nov;55(3):238-45. doi: 10.1016/j.ymeth.2011.10.006. Epub 2011 Oct 25. Methods. 2011. PMID: 22056346 Review.
On this basis, radiolabeled iodinated-MIBG (I-131-MIBG) has been introduced as a molecular nuclear therapy in the management of neuroendocrine tumors, including neuroblastoma, pheochromocytoma, paraganglioma, neuroendocrine carcinomas, and other rare neuroendocrine tumors. …
On this basis, radiolabeled iodinated-MIBG (I-131-MIBG) has been introduced as a molecular nuclear therapy in the management of neuroendocri …
Therapeutic goals in patients with pheochromocytoma: a guide to perioperative management.
Azadeh N, Ramakrishna H, Bhatia NL, Charles JC, Mookadam F. Azadeh N, et al. Ir J Med Sci. 2016 Feb;185(1):43-9. doi: 10.1007/s11845-015-1383-5. Epub 2015 Dec 9. Ir J Med Sci. 2016. PMID: 26650752 Review.
The mainstay of medical therapy in order to optimize patients for surgery includes: alpha-blockers, beta-blockers, calcium channel blocker and other agents to achieve normal blood pressure, heart rate, as well as normal volume status. Understanding the pathophysiology of pheoc …
The mainstay of medical therapy in order to optimize patients for surgery includes: alpha-blockers, beta-blockers, calcium channel blocker a …
1,931 results